blue-overlay
blue-overlay

Press Releases

August 29, 2017

CELGENE CORPORATION EXERCISED OPTION TO EXTEND STRATEGIC COLLABORATION SCOPE AND TERM WITH FORMA THERAPEUTICS

FORMA to investigate drug candidates across multiple therapeutic areas FORMA retains full control of portfolio through early clinical development and retains U.S. rights to products…

April 10, 2017

FORMA THERAPEUTICS DELIVERS TWO KEY OBJECTIVES IN COLLABORATION WITH CELGENE CORPORATION TO ADVANCE PROTEIN HOMEOSTASIS MEDICINES TO BENEFIT PATIENTS

WATERTOWN, Mass. – April 10, 2017 – FORMA Therapeutics announced today that it has successfully completed two additional objectives under its strategic collaboration agreement with…

March 13, 2017

FORMA THERAPEUTICS ANNOUNCES ACHIEVEMENT OF FIRST CLINICAL DEVELOPMENT MILESTONE IN PARTNERSHIP WITH BOEHRINGER INGELHEIM

WATERTOWN, Mass. – March 13, 2017 – FORMA Therapeutics, a clinical-stage and fully integrated discovery and development company, today announced the achievement of a clinical…

February 21, 2017

FORMA THERAPEUTICS AWARDED GRANT FROM MICHAEL J. FOX FOUNDATION FOR PARKINSON’S RESEARCH

FORMA Therapeutics receives grant from MJFF and expands translational research into neurodegenerative diseases through alliance with University of Liverpool and Medical Research Council. WATERTOWN, Mass….

October 11, 2016

FORMA THERAPEUTICS APPOINTS JIM WINKLER, PH.D., VICE PRESIDENT, DISCOVERY AND TRANSLATIONAL BIOLOGY

WATERTOWN, Mass. — October 11, 2016 — FORMA Therapeutics, a clinical-stage and fully integrated research and development company, today announced the appointment of Jim Winkler,…

News & Events

October 18, 2017 / Nature (Publication)

Molecular basis of USP7 inhibition by selective small-molecule inhibitors

— Stephanos Ioannidis, Head of Early Portfolio (Nature (2017) doi:10.1038/nature24451)

October 10, 2017 / Oxford Global Drug Discovery USA Congress (Presentation)

Design And Optimization Of Novel Benzopiperazines As Potent Inhibitors Of BET Bromodomains

— San Diego, CA / Katherine Kayser-Bricker (Principal Scientist, Head of Automated Synthesis, FO)

September 27, 2017 / Discovery on Target (Presentation)

Mining the Deubiquitinase Family for Novel Drugs Utilizing FORMA’s Drug Discovery Engine

— Boston, MA / Stephanos Ioannidis (Head of Early Portfolio)

September 21, 2017 / BioCentury (News)

On Your Marks: How the slowly-progressing epigenetics field is moving away from cancer

— Lauren Martz, Senior Writer (featuring John Hohneker, MD; Head of R & D, FORMA Therapeutics)

September 19, 2017 / CellPress (Publication)

Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6

— Maureen Caligiuri; Bingsong Han; David R. Lancia; Xiaozhang Zheng (Cell Reports 20, 2860–2875, September 19, 2017)